US Diverticular Disease Market Research Report: By Type (Diverticulosis, Diverticulitis), By Treatment (Medication, Supportive Care, Surgery), By Diagnosis (CT Scan, Ultrasound, Urine Test, Blood Test) and By End User (Hospitals, Specialty Centers) - Forecast to 2035

US Diverticular Disease Market Overview:

As per MRFR analysis, the US Diverticular Disease Market Size was estimated at 393.39 (USD Million) in 2023. The US Diverticular Disease Market Industry is expected to grow from 421.34(USD Million) in 2024 to 1,040.3 (USD Million) by 2035. The US Diverticular Disease Market CAGR (growth rate) is expected to be around 8.564% during the forecast period (2025 - 2035).

Key US Diverticular Disease Market Trends Highlighted

The US Diverticular Disease Market is witnessing significant trends driven by the increasing prevalence of diverticular diseases among the aging population. With over 60% of Americans over the age of 60 experiencing some form of diverticular disease, the demand for better treatment options and dietary management strategies is growing. This rise in cases is also prompting a heightened awareness of digestive health, thereby driving healthcare providers to develop tailored therapies and nutritional products that address the needs of affected individuals. Advanced treatments, including minimally invasive surgical procedures and novel pharmacological therapies, are emerging as key market drivers, enhancing patient outcomes and reducing recovery times.In recent times, there is a notable shift towards preventive healthcare. More healthcare practitioners in the US are encouraging dietary changes and preventive screenings, which presents an opportunity for companies to develop products like fiber supplements, probiotics, and educational resources that focus on gut health. Additionally, digital health solutions, including mobile applications that monitor and guide patients in dietary habits, are gaining traction. Research and development in the US are also directing attention towards understanding the microbiome's role in diverticular disease, opening avenues for innovative treatments that could cater specifically to the underlying causes rather than just managing symptoms.The introduction of health insurance policies that cover preventive measures and treatments for diverticular disease further enhances the market landscape, promoting early diagnosis and effective management. Overall, these trends reflect a proactive shift in addressing diverticular disease within the US, emphasizing a combination of prevention, early intervention, and advanced treatment options.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

US Diverticular Disease Market Drivers

Increasing Prevalence of Diverticular Disease

The elevation in the prevalence of diverticular disease in the United States has been a significant driver for the US Diverticular Disease Market Industry. According to the Centers for Disease Control and Prevention (CDC), about 250,000 individuals are hospitalized each year due to diverticulitis, and it affects roughly 50% of adults over age 60. As the aging population in the U.S. continues to grow, with projections showing that by 2030, approximately 20% of the population will be over the age of 65, the number of individuals potentially suffering from diverticular disease is expected to rise.The National Institute of Diabetes and Digestive and Kidney Diseases has pointed out that the prevalence of this disease correlates directly with the aging demographic, creating an expanding market for treatment options and interventions. This rise emphasizes the need for increased healthcare resources devoted to the US Diverticular Disease Market.

Advancements in Medical Technologies and Surgical Procedures

The ongoing advancements in medical technologies and surgical procedures related to diverticular disease treatment provide a robust foundation for the growth of the US Diverticular Disease Market Industry. Innovative minimally invasive surgical techniques and improved imaging technologies have transformed how diverticular disease is diagnosed and treated. According to the American College of Surgeons, laparoscopic procedures have decreased recovery times and hospital stays, making surgical interventions more appealing for patients.Research indicates that the adoption of such minimally invasive technologies has grown by over 50% in the last five years, which is driving demand for targeted treatment options. This technological evolution signifies not only an improvement in patient outcomes but also a surge in healthcare expenditure toward these advanced treatments, further bolstering the US Diverticular Disease Market.

Rising Awareness and Education on Digestive Health

There has been a significant increase in awareness and education surrounding digestive health in the United States, which serves as a key driver for the US Diverticular Disease Market Industry. Campaigns led by organizations like the American Gastroenterological Association have been particularly effective in informing the public about the risks, symptoms, and treatments associated with diverticular disease. A survey conducted by the National Institute of Health revealed that educational efforts have increased awareness among patients and healthcare providers, leading to a 25% growth in early diagnosis of diverticular disease over the past three years.This heightened awareness drives more individuals to seek medical advice and treatment, supporting an expanding US Diverticular Disease Market.

Increased Healthcare Expenditure for Digestive Disorders

The rising healthcare expenditure in the United States is another major driver influencing the growth of the US Diverticular Disease Market Industry. The U.S. Department of Health and Human Services has reported that total healthcare spending is expected to reach approximately USD 6 trillion by 2027, fueled by a focus on treating chronic conditions including diverticular disease. This significant investment reflects a broader trend where hospitals and clinics are prioritizing better gastrointestinal care.The increase in healthcare spending allows for research and development into more effective treatments and medications, addressing the specific needs of diverticular disease patients. Consequently, this investment in healthcare infrastructure fundamentally supports the expansion and accessibility of the US Diverticular Disease Market.

US Diverticular Disease Market Segment Insights:

Diverticular Disease Market Type Insights

The US Diverticular Disease Market is a significant segment within the broader healthcare landscape, particularly focusing on conditions such as Diverticulosis and Diverticulitis. Diverticulosis is characterized by the formation of pouches in the colonic wall, which, while often asymptomatic, can lead to complications if not managed properly. This condition is prevalent among the aging population and is believed to affect a considerable percentage of adults over 60 years old, making it a critical area for healthcare attention. On the other hand, Diverticulitis occurs when these pouches become inflamed or infected, leading to symptoms such as abdominal pain, fever, and changes in bowel habits. This often necessitates medical treatment and can sometimes require surgery. The increasing incidence of diverticular disease in the US, attributed to lifestyle factors such as diet and sedentary behavior, has driven a surge in demand for comprehensive treatment options and preventative measures.The US Diverticular Disease Market segmentation highlights the importance of understanding both these conditions, as they often coexist but require different management strategies. Diverticulosis management focuses significantly on dietary modifications and lifestyle changes, aiming to prevent progression to diverticulitis, which may involve more advanced medical interventions. The evolution in treatment protocols and increased awareness among healthcare providers and patients are key driving factors contributing to market growth.Healthcare providers are increasingly recognizing the need for patient education regarding the management of these diseases, which in turn influences treatment outcomes and reduces healthcare costs over time. Additionally, advancements in diagnostic technologies and a better understanding of risk factors are creating opportunities for early detection and intervention, thus improving patient care.As the US population continues to age, the implications of diverticular disease and its treatments will remain a pertinent focus for the healthcare industry. The overall market dynamics will be influenced by a mix of demographic changes, evolving dietary habits, and an increasing emphasis on preventive healthcare measures. With these insights, stakeholders in the US Diverticular Disease Market will have to strategize effectively to address the growing needs associated with Diverticulosis and Diverticulitis.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Diverticular Disease Market Treatment Insights

The Treatment segment of the US Diverticular Disease Market is a crucial component, focusing on various approaches to manage and alleviate symptoms associated with the condition. This segment includes Medication, Supportive Care, and Surgery, each contributing uniquely to addressing patient needs. Medication represents a primary response to manage acute symptoms and prevent disease progression, reflecting the trends toward pharmacological advances and improved patient adherence. Supportive Care plays a pivotal role in enhancing patients' quality of life, encompassing dietary management and counseling, tailored to individuals' conditions.Surgery, although considered when complications arise, remains significant for those with severe or recurrent cases, emphasizing the need for surgical interventions in managing advanced diverticular disease. As the population ages in the US, leading to increased incidences of diverticular disease, the Treatment segment is projected to grow, driven by evolving clinical guidelines and an uptick in healthcare expenditure. The growing focus on individualized patient treatment plans represents an opportunity for advanced therapeutic approaches, aligning with the increasing demand for specialized care in chronic conditions like diverticular disease.The US Diverticular Disease Market Statistics indicate that with advancements in medical technology and treatment strategies, this segment will continue to be a focal point for healthcare providers and patients alike.

Diverticular Disease Market Diagnosis Insights

The Diagnosis segment of the US Diverticular Disease Market plays a critical role in effective disease management, enabling early detection and treatment. Within this segment, diverse diagnostic methods are employed to assess diverticular disease, including CT Scans, Ultrasounds, Urine Tests, and Blood Tests. CT Scans are particularly significant, offering high-resolution images that assist in identifying complications and guiding treatment options. Ultrasounds are non-invasive and can be particularly useful in assessing the presence of diverticula without exposing patients to radiation.Urine and Blood Tests serve as essential adjuncts, helping to identify associated infections or complications. The collective advancement of these diagnostic tools strengthens the accuracy and efficiency of diagnosis, enhancing patient outcomes. This robust approach to diagnosis not only aligns with the growing demand for health services in the US but also reflects trends towards minimally invasive procedures and quicker diagnostic turnaround times, driven by technological innovations and increased healthcare awareness in the population. The US government has recognized the notable rise in diverticular disease incidences, further emphasizing the importance of precise diagnostics to facilitate effective healthcare strategies.Overall, the Diagnosis segment holds significant value in shaping the landscape of diverticular disease management in the US.

Diverticular Disease Market End User Insights

The US Diverticular Disease Market demonstrates significant engagement from various End Users, notably Hospitals and Specialty Centers. Hospitals play a crucial role as they cater to a large population seeking treatment for diverticular disease, often providing advanced diagnostic facilities and comprehensive care. They possess the necessary infrastructure and skilled staff to manage a diverse range of complications associated with this condition. On the other hand, Specialty Centers offer focused treatment plans and personalized care, emphasizing minimally invasive procedures and innovative therapies, attracting patients looking for specialized attention.This sector’s growth is driven by factors such as the increasing prevalence of diverticular disease in the aging population and the rising awareness of effective treatment options. Additionally, advancements in diagnostic techniques and surgical treatments present opportunities for further market expansion. The interplay between these End Users reflects a growing recognition of the importance of a multifaceted approach in managing diverticular disease, contributing to improved patient outcomes and overall market growth. The segmentation in the US Diverticular Disease Market points to a dynamic landscape, shaping how care is delivered and optimized for patient needs.

US Diverticular Disease Market Key Players and Competitive Insights:

The US Diverticular Disease Market is characterized by a competitive landscape shaped by a multitude of factors including the increasing prevalence of diverticulitis and the growing awareness of gastrointestinal health. As the healthcare ecosystem continues to evolve with advancements in therapeutic options, the competitive insights reveal a market that is not only addressing existing treatment gaps but also striving for innovative solutions to meet patient needs. The players in this market are leveraging their strengths to enhance patient outcomes while navigating the complexities of regulatory frameworks and market demands. A deeper understanding of competitive strategies, product offerings, and market positioning is essential for stakeholders looking to thrive in this dynamic environment.Merck and Co has established a significant presence in the US Diverticular Disease Market through its dedication to research and development aimed at enhancing gastrointestinal health. The company has cultivated strong relationships with healthcare providers and stakeholders, facilitating a deeper understanding of diverticular disease management. Merck and Co's extensive portfolio includes key therapies that focus on reducing the recurrence of diverticulitis, and its ability to navigate complex regulatory pathways has cemented its reputation as a trusted name in the field. The company’s strong emphasis on clinical evidence and patient-centered approaches further bolster its market position, allowing for a robust engagement with both healthcare professionals and patients alike.Bristol Myers Squibb has emerged as a formidable player in the US Diverticular Disease Market, driven by its innovative therapeutic offerings that address both the acute and chronic manifestations of diverticular disease. With a focus on enhancing treatment paradigms, Bristol Myers Squibb has developed a range of key products aimed at improving gastrointestinal health. The company's commitment to advancing research in this area has been bolstered by strategic mergers and acquisitions that have expanded its capabilities and market reach. This integration of new technologies and therapeutic approaches has reinforced Bristol Myers Squibb's position within the market, enabling it to effectively address patient needs while adapting to evolving industry trends. The combination of an established market presence and a strong pipeline of potential therapies continues to strengthen Bristol Myers Squibb's competitive edge, allowing it to remain a significant contributor to advancements in diverticular disease management within the US.

Key Companies in the US Diverticular Disease Market Include:

Merck and Co

Bristol Myers Squibb

Celgene

Novartis

AstraZeneca

Takeda Pharmaceuticals

Gilead Sciences

Eli Lilly and Company

Horizon Therapeutics

Sobi

Sarepta Therapeutics

Pfizer

Amgen

AbbVie

Johnson and Johnson

US Diverticular Disease Market Industry Developments

Recent developments in the US Diverticular Disease Market have been shaped by significant advancements and strategic movements by key players such as Merck and Co., Bristol Myers Squibb, and Takeda Pharmaceuticals. The market is experiencing a growth surge reflecting increased awareness of diverticular disease and the rising prevalence of gastrointestinal disorders among the aging population. In September 2023, Gilead Sciences announced a focused initiative on digestive diseases that aligns with their broader pipeline, including potential therapies for diverticular disease. Meanwhile, Bristol Myers Squibb concluded its acquisition of Celgene in November 2019, enhancing its portfolio in gastrointestinal therapeutics. Merger and acquisition activities continue to reshape the competitive landscape, as companies like Novartis and Pfizer explore collaborations to strengthen their product offerings. Additionally, AstraZeneca's commitment to Research and Development has also contributed to innovations in the market. Recent data from the CDC reflects rising treatment demand, leading to increased investments and expansions among the aforementioned companies, creating a dynamic environment for new technologies and treatments in diverticular disease management, with continuous updates on regulatory approvals further propelling market interest.

US Diverticular Disease Market Segmentation Insights

Diverticular Disease Market Type Outlook

Diverticulosis

Diverticulitis

Diverticular Disease Market Treatment Outlook

Medication

Supportive Care

Surgery

Diverticular Disease Market Diagnosis Outlook

CT Scan

Ultrasound

Urine Test

Blood Test

Diverticular Disease Market End User Outlook

Hospitals

Specialty Centers

Report Scope:

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	393.39(USD Million)
MARKET SIZE 2024	421.34(USD Million)
MARKET SIZE 2035	1040.3(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	8.564% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Merck and Co, Bristol Myers Squibb, Celgene, Novartis, AstraZeneca, Takeda Pharmaceuticals, Gilead Sciences, Eli Lilly and Company, Horizon Therapeutics, Sobi, Sarepta Therapeutics, Pfizer, Amgen, AbbVie, Johnson and Johnson
SEGMENTS COVERED	Type, Treatment, Diagnosis, End User
KEY MARKET OPPORTUNITIES	Increasing demand for dietary supplements, Advancements in minimally invasive treatments, Growing awareness of preventive care, Expansion of telehealth services, Rising prevalence of diverticular disease
KEY MARKET DYNAMICS	increasing prevalence of diverticular disease, rising awareness and diagnosis, advancements in treatment options, aging population impact, dietary lifestyle changes
COUNTRIES COVERED	US